Reversal on Reverse Doctrine of Equivalents
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Bryant Chen & Nathan D. Reeves
STEUBEN FOODS, INC. v. SHIBUYA HOPPMANN CORPORATION
Before Moore, Hughes, and Cunningham. Appeal from the United States District Court for the District of Delaware.
Summary: Conflicting expert testimony constituted substantial evidence supporting the jury’s rejection of a reverse doctrine of equivalents argument.
Plaintiff Steuben sued Defendant Shibuya for infringing three patents. After a jury found the patents valid and infringed, the defendant moved for JMOL of noninfringement. For one of the patents, the defendant argued that its product did not infringe under the reverse doctrine of equivalents (RDOE), which holds that a product does not infringe if its principle of operation is sufficiently different from that of the asserted claim. The district court granted the motion, finding that the defendant’s expert provided testimony supporting the RDOE argument and that the plaintiff’s contrary expert testimony was wrong as a matter of law. The plaintiff appealed.
The Federal Circuit reversed, holding that the district court erred in relying on RDOE to overturn the jury’s verdict of infringement. As an initial matter, the court declined to decide whether the RDOE, a common law doctrine, survived the 1952 Patent Act. The court acknowledged that it has never affirmed a noninfringement finding based on the RDOE, and it once again refused to decide whether the doctrine is viable. Instead, the court ruled that the plaintiff’s expert testimony constituted substantial evidence supporting the jury’s rejection of the defendant’s RDOE argument. The court stated that, because the jury heard conflicting expert testimony regarding the principle of operation, a factual issue, it is presumed to have resolved the conflict in favor of the verdict. Accordingly, the Federal Circuit reversed and reinstated the jury’s verdict of infringement.
Editor: Sean Murray
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…